We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-Speed NanoPCR Technology Diagnoses COVID-19 in 20 Minutes with Zero False Positive and False Negative

By LabMedica International staff writers
Posted on 09 Dec 2020
A new high-speed nanoPCR technology for point-of-care (POC) diagnosis of COVID-19 can accurately diagnose the infection in less than 20 minutes, with zero false positive and false negative.

The nanoPCR technology developed by scientists at the Center for Nanomedicine (CNM) within the Institute for Basic Science (IBS; Seoul, Korea) can diagnose COVID-19 while retaining the accuracy of conventional reverse transcription polymerase chain reaction (RT-PCR) technology. The novel nanoPCR technology that can be used for the decentralized, POC diagnosis of COVID-19 uses the same underlying principle as the standard diagnosis method of RT-PCR to detect viral RNA, but also features a vast improvement in speed using hybrid nanomaterials and a miniaturized form factor which allows portability.

Illustration
Illustration

The research team utilized a magneto-plasmonic nanoparticle (MPN) that is comprised of magnetic material in its core and a gold shell that exhibits plasmonic effects. By applying MPNs to PCR, they developed 'nanoPCR' which greatly improves the speed of RT-PCR while retaining highly accurate detection. Plasmonic properties of MPN refer to its ability to convert light energy into thermal energy, and by using this it was possible to shorten the thermocycling step of RT-PCR from 1 - 2 hours to within 11 minutes. In addition, the strong magnetic property of MPN allows an external magnetic field to clear MPNs from the PCR solution to allow for fluorescent detection of the amplified genes. The nanoPCR is capable of detecting even a small amount of genes (~3.2 copies/μl) accurately while simultaneously amplifying and detecting genetic material with high sensitivity and specificity.

The researchers tested nanoPCR under clinical settings through the patient specimen tests. During the test, 150 subjects with or without COVID-19 infection were accurately diagnosed using this technology (75 positives, 75 negative samples; zero false-negatives and false-positives). The level of sensitivity and specificity was found to be equivalent to that of the conventional RT-PCR (~99%). In addition to high reliability, the whole diagnostic process was considerably fast, as on average it took about 17 minutes for the diagnosis of one specimen.

In addition, the researchers showed the possibility of improving the analytical throughput by applying a Ferris wheel system to load multiple samples at once, which would allow for simultaneous testing of many samples from multiple patients. Importantly, the nanoPCR equipment is very compact in size (15 × 15 × 18 cm) and weight (3 kg), which allows it to be portable. All of this would pave the way for rapid, decentralized testing of patients for the POC diagnosis.

"Through the improvement and miniaturization of the PCR technology, we have shown that it is possible to perform PCR based POC diagnosis in the field quickly," said Professor Cheon Jinwoo, director of CNM.

Related Links:
Institute for Basic Science


New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes